ARTL Profile
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative therapies aimed at modulating the endocannabinoid system. The company's pipeline is centered around novel drug candidates designed to address various medical conditions by leveraging the endocannabinoid system's regulatory mechanisms.
Among Artelo's key product candidates is ART27.13, a synthetic G protein-coupled receptor agonist currently in Phase 1b/2a clinical trials. This compound is being investigated for its potential to treat anorexia associated with cancer, a serious condition that impacts patients' quality of life and treatment outcomes. Another notable candidate is ART12.11, a synthetic cannabidiol cocrystal, which is being developed for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD). This drug aims to harness the therapeutic properties of cannabidiol to manage these challenging conditions.
Additionally, Artelo is advancing ART26.12, a fatty acid binding protein 5 (FABP5) inhibitor. This candidate is being evaluated for its potential use in treating prostate and breast cancers, as well as PTSD. The company's research includes a collaboration with Trinity College Dublin to explore ART27.13’s efficacy in addressing cancer cachexia, a debilitating condition characterized by severe weight loss and muscle wasting associated with cancer.
Originally incorporated as Reactive Medical, Inc. in 2011 and rebranded as Artelo Biosciences, Inc. in April 2017, the company is headquartered in Solana Beach, California. Artelo Biosciences continues to focus on harnessing the therapeutic potential of the endocannabinoid system to develop groundbreaking treatments for a range of serious and underserved medical conditions.
|
